Under the deal, biOasis will conduct certain experiments using its technology, as it relates to the delivery of therapeutic compounds owned by UCB for CNS disorders.
biOasis Technologie CEO Rob Hutchison said biopharmaceutical company UCB has a broad global presence and a deep pipeline.
"We”re very pleased to be commencing this collaboration with UCB whom we believe have some tremendous targets for our Transcend vector," Hutchison added.
"The work will start over the next few months and carry into the New Year.
"We are looking forward to working with the UCB scientists to successfully achieve the objectives we have set out in agreement."
Financial details of the transaction have not been disclosed.